Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Prepublished online as a Blood First Edition Paper on May 8, 2003; DOI 10.1182/blood-2002-10-3264.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-10-3264v1
102/5/1622    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gatto, S.
Right arrow Articles by Beran, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gatto, S.
Right arrow Articles by Beran, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted October 29, 2002
Accepted April 25, 2003

Contribution of B-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndromes (MDS)

Simona Gatto, Greg Ball, Francesco Onida, Hagop M Kantarjian, Elihu H Estey, and Miloslav Beran*

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Center for Professional Excellence, The Methodist Hospital, Houston, TX, USA

* Corresponding author; email: mberan{at}mdanderson.org.

Prospective analysis of the importance of the plasma levels of {beta}-2 microglobulin (B2M) in 553 patients with myelodsyplastic syndromes (MDS) found that B2M is an independent prognostic variable for survival with weighted significance second only to the karyotype. The incorporation of the B2M covariate into risk assessment of MDS patients added significantly to the power of the IPSS to stratify MDS patients into risk categories. Our results further document that the two objectively measured covariates, which display the highest power to predict survival, i.e. karyotype and B2M, can alone be used for risk stratification. While the results must be verified in an independent population, our data strongly recommend routine measurement of B2M in patients with MDS.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A.-M. Tsimberidou, H. M. Kantarjian, S. Wen, S. O'Brien, J. Cortes, W. G. Wierda, C. Koller, S. Pierce, M. Brandt, E. J. Freireich, et al.
The Prognostic Significance of Serum {beta}2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients
Clin. Cancer Res., February 1, 2008; 14(3): 721 - 730.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020